TPX2 and hepatocellular carcinoma: Moreover, knockdown of TPX2 via its siRNA in MHCC97-H cells led to a deceleration of sorafenib metabolism and/or clearance in HCC tissues (Fig. 5D, F) and an increase in the t1/2 value of sorafenib (Table 7).